Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers

NCT07743593 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

505

Enrollment

OTHER

Sponsor class

Conditions

Cryptococcal Antigenemia
HIV-1-infection
Cryptococcal Infection
Cryptococcal Meningitis

Interventions

DRUG: Immediate ART Initiation
DRUG: Delayed ART Initiation
DRUG: 10-Week Fluconazole
DRUG: 24-Week Fluconazole

Sponsor

University of Minnesota